Generic Medicine Info
Indications and Dosage
Bowel decontamination before surgery, Susceptible infections
Adult: In combination with other antibacterials. Use as directed by product information.
Renal Impairment
Dose reduction may be necessary.
Pregnancy (prior to delivery); infants within 1-2 mth of birth; porphyria; severe renal or hepatic failure; blood disorders; hypersensitivity; SLE.
Special Precautions
Adequate hydration is necessary to reduce the risk of crystalluria. Discontinue immediately if rash appears. Renal or hepatic failure; asthma or history of allergy; elderly; G6PD deficiency; AIDS patients (especially those on trimethoprim).
Adverse Reactions
GI effects, hypersensitivity reactions, nephrotoxic reactions, blood disorders, hepatic disorders, CV effects, hypoglycaemia, hypothyroidism, neurological reactions, pseudomembranous colitis and kernicterus in premature neonates.
Potentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome, anaphylaxis.
Drug Interactions
Potentiates effect of oral anticoagulants, methotrexate and phenytoin; possible failures of hormonal contraceptives; enhanced antidiabetic effect of sulfonylurea compounds; antagonism with PABA and its derivatives; associated with decrease in plasma-ciclosporin concentrations.
Lab Interference
Urea, creatinine and urinary glucose and urobilinogen.
Mechanism of Action: Phthalylsulfathiazole is a sulfonamide with properties similar to those of sulfamethoxazole. Sulfonamides have a similar structure to p-aminobenzoic acid (PABA) and interfere with the nucleic acid synthesis in sensitive microorganisms by blocking the conversion of PABA to the reduced form of folic acid, co-enzyme dihydrofolic acid. Primarily bacteriostatic, it may exert bactericidal effects where concentrations of thymine are low in surrounding medium. It is used to treat infections and for bowel decontamination before surgery.
Absorption: Poorly absorbed, approx 95% remaining in the intestine.
Metabolism: Slowly hydrolysed to sulfathiazole.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Phthalylsulfathiazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in